Beyond GLP‑1s: The race for next‑gen obesity drugs starts in the preclinical models

Summary

Industry analysis discussing limitations of current GLP-1 obesity drugs including efficacy plateaus and muscle loss, with companies exploring new mechanisms and multitarget approaches to address unmet needs in obesity treatment.